Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for engagement with investors [1][4] Company Overview - Sagimet is developing fatty acid synthase (FASN) inhibitors aimed at treating diseases caused by the overproduction of palmitate [3] - The lead drug candidate, denifanstat, is an oral, once-daily selective FASN inhibitor for metabolic dysfunction associated with steatohepatitis (MASH) [3] - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [3] - The FASCINATE-2 Phase 2b clinical trial of denifanstat has been successfully completed with positive results [3] - Sagimet has initiated a Phase 1 pharmacokinetic clinical trial combining denifanstat with resmetirom for MASH patients [3] - A Phase 1 first-in-human clinical trial for another FASN inhibitor, TVB-3567, has also been initiated, targeting acne treatment in the U.S. [3] Upcoming Events - The company will participate in the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with a fireside chat starting on October 21 at 7am ET [4] - Sagimet will also be present at the Guggenheim Annual Healthcare Innovation Conference in Boston, MA, on November 10, 2025, with a fireside chat at 11:30am ET [4] - Additionally, the company will attend the UBS Global Healthcare Conference in Palm Beach, FL, on November 11, 2025 [4]